Doug Ingram, Sarepta Therapeutics CEO (Michael Nagle/Bloomberg via Getty Images)
May 6, 2025 09:28 PM EDTUpdated 06:55 AM
Pharma
FDA+

Sarep­ta’s stock plum­mets af­ter Prasad ap­point­ment, low Ele­v­idys sales

Lei Lei Wu

News Reporter

Sarep­ta Ther­a­peu­tics had a bad day in Wash­ing­ton. And then a worse one on Wall Street.

On Tues­day, the com­pa­ny’s stock fell 27% fol­low­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times